Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum
Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum. Women with ovarian cancer completed...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology Jg. 146; H. 2; S. 386 - 391 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Elsevier Inc
01.08.2017
|
| Schlagworte: | |
| ISSN: | 0090-8258, 1095-6859, 1095-6859 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum.
Women with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media.
Four hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. >50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease.
Women with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease.
•Women with ovarian cancer prioritize overall survival however also deeply value quality of life.•The expectation of “cure” drives women with ovarian cancer to accept many treatment toxicities.•Acceptance of treatment side effects wanes when the goal is remission and stable disease. |
|---|---|
| AbstractList | Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum.
Women with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media.
Four hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. >50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease.
Women with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease. Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum. Women with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media. Four hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. >50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease. Women with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease. •Women with ovarian cancer prioritize overall survival however also deeply value quality of life.•The expectation of “cure” drives women with ovarian cancer to accept many treatment toxicities.•Acceptance of treatment side effects wanes when the goal is remission and stable disease. Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum.OBJECTIVESWomen with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum.Women with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media.METHODSWomen with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media.Four hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. >50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease.RESULTSFour hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. >50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease.Women with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease.CONCLUSIONSWomen with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease. Abstract Objectives Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to determine whether survivors' acceptance of treatment side effects also changes over the disease continuum. Methods Women with ovarian cancer completed an online survey focusing on survivors' goals and priorities. The survey was distributed through survivor networks and social media. Results Four hundred and thirty-four women visited the survey website and 328 (76%) completed the survey. Among participants, 141 (43%) identified themselves as having ever recurred, 119 (36%) were undergoing treatment at the time of survey completion and 86 (26%) had received four or more chemotherapy regimens. Respondents' goals of care were cure for 115 women (35%), remission for 156 (48%) and stable disease for 56 (17%). When asked what was most meaningful, 148 women (45%) reported overall survival, 135 (41%) reported quality of life and 40 (12%) reported progression-free survival. > 50% of survivors were willing to tolerate the following symptoms for the goal of cure: fatigue (283, 86%), alopecia (281, 86%), diarrhea (232, 71%), constipation (227, 69%), neuropathy (218, 66%), arthralgia (210, 64%), sexual side effects (201, 61%), reflux symptoms (188, 57%), memory loss (180, 55%), nausea/vomiting (180, 55%), hospitalization for treatment side effects (179, 55%) and pain (169, 52%). The rates of tolerance for most symptoms decreased significantly as the goal of treatment changed from cure to remission to stable disease. Conclusions Women with ovarian cancer willingly accept many treatment side effects when the goal of treatment is cure, however become less accepting when the goal is remission and even less so when the goal is stable disease. Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease. |
| Author | Koontz, Laura M. Shyne, Savannah Klingenberg, Bernhard Chern, Jing-Yi Blank, Stephanie V. Ellis, Annie E. Fields, Jessica C. Frey, Melissa K. |
| Author_xml | – sequence: 1 givenname: Melissa K. surname: Frey fullname: Frey, Melissa K. email: mkf2002@med.cornell.edu organization: Weill Cornell Medicine, United States – sequence: 2 givenname: Annie E. surname: Ellis fullname: Ellis, Annie E. organization: Ovarian Cancer Research Fund Alliance (OCRFA), United States – sequence: 3 givenname: Laura M. surname: Koontz fullname: Koontz, Laura M. organization: Ovarian Cancer Research Fund Alliance (OCRFA), United States – sequence: 4 givenname: Savannah surname: Shyne fullname: Shyne, Savannah organization: SHARE, United States – sequence: 5 givenname: Bernhard surname: Klingenberg fullname: Klingenberg, Bernhard organization: Williams College, United States – sequence: 6 givenname: Jessica C. surname: Fields fullname: Fields, Jessica C. organization: Weill Cornell Medicine, United States – sequence: 7 givenname: Jing-Yi surname: Chern fullname: Chern, Jing-Yi organization: New York University Langone Medical Center, United States – sequence: 8 givenname: Stephanie V. surname: Blank fullname: Blank, Stephanie V. organization: Icahn School of Medicine at Mount Sinai, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28602549$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl2L1DAYhYOsuLOrv0CQ3OlNxzdp0zaIC7L4BQt7oV6HNH07m7GTjElanH9v6ux6sSBzFQjPcwLn5IKcOe-QkJcM1gxY_Xa7PmwOzq85sGYNYg1cPiErBlIUdSvkGVkBSChaLtpzchHjFgBKYPwZOedtDVxUckV-3846WO2o0c5goHEKs519iK-pNgb3abmmfqApoE47dIlG2yPFYUCTIsXZjzNGqiPdeD3GBTU6IDV32m2yOefQdIcP-ca7ZN007Z6Tp0Pm8cX9eUl-fPr4_fpLcXP7-ev1h5vCVFWTiq7RrGZDxztkehAloBy6pq-lEGha3Q09a1B3wsi-4rUcsBSSY4OmkrVuJC8vyZtj7j74XxPGpHY2GhxH7dBPUTEJbSNbqCCjr-7Rqdthr_bB7nQ4qIe2MlAeARN8jAGHfwgDtWyiturvJmrZRIFQeZNsyUeWsUknm5sI2o4n3PdHF3NFs8WgorGYm-xtyP2r3tsT_tUj34zWWaPHn3jAuPVTcLl9xVTkCtS35ccsH4Y1JbStEDng3f8DTj7_B1aF1Hw |
| CitedBy_id | crossref_primary_10_1016_j_tjog_2019_11_032 crossref_primary_10_1016_j_pec_2021_08_016 crossref_primary_10_1177_10499091211064242 crossref_primary_10_1016_j_hoc_2018_07_009 crossref_primary_10_1016_j_pec_2023_108099 crossref_primary_10_1016_j_ygyno_2017_10_004 crossref_primary_10_1080_0284186X_2018_1546061 crossref_primary_10_1016_j_ygyno_2020_08_016 crossref_primary_10_2147_IJWH_S366680 crossref_primary_10_3390_jcm13144213 crossref_primary_10_1093_oncolo_oyae093 crossref_primary_10_1016_j_ajog_2020_06_049 crossref_primary_10_1016_j_ygyno_2020_04_697 crossref_primary_10_1002_fsn3_3534 crossref_primary_10_1186_s40814_018_0283_7 crossref_primary_10_1177_10732748211068963 crossref_primary_10_1136_ijgc_2020_002001 crossref_primary_10_1007_s00520_019_05216_y crossref_primary_10_1097_CR9_0000000000000032 |
| Cites_doi | 10.1634/theoncologist.2010-S1-11 10.1016/j.ygyno.2014.09.008 10.1056/NEJMsa012528 10.1007/s13187-011-0260-9 10.1016/j.ygyno.2015.11.030 10.1111/j.1365-2354.2006.00699.x 10.1136/bmj.38103.423576.55 10.1007/s11606-007-0104-9 10.1016/j.ygyno.2013.11.008 10.1111/j.1541-0420.2006.00525.x 10.4103/2347-5625.160971 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Inc. Elsevier Inc. Copyright © 2017 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2017 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2017 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ygyno.2017.05.029 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1095-6859 |
| EndPage | 391 |
| ExternalDocumentID | 28602549 10_1016_j_ygyno_2017_05_029 S0090825817308855 1_s2_0_S0090825817308855 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU LCYCR 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c447t-b7a161fb2be1af530e9fb7d6955ec8abfd17eab5c9d4269fe3592e7ec496a7923 |
| ISSN | 0090-8258 1095-6859 |
| IngestDate | Mon Sep 29 04:25:03 EDT 2025 Mon Jul 21 05:59:52 EDT 2025 Sat Nov 29 04:40:25 EST 2025 Tue Nov 18 22:29:41 EST 2025 Fri Feb 23 02:31:08 EST 2024 Sun Feb 23 10:20:09 EST 2025 Tue Oct 14 19:35:14 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Copyright © 2017 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c447t-b7a161fb2be1af530e9fb7d6955ec8abfd17eab5c9d4269fe3592e7ec496a7923 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 28602549 |
| PQID | 1908798040 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1908798040 pubmed_primary_28602549 crossref_primary_10_1016_j_ygyno_2017_05_029 crossref_citationtrail_10_1016_j_ygyno_2017_05_029 elsevier_sciencedirect_doi_10_1016_j_ygyno_2017_05_029 elsevier_clinicalkeyesjournals_1_s2_0_S0090825817308855 elsevier_clinicalkey_doi_10_1016_j_ygyno_2017_05_029 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-08-01 |
| PublicationDateYYYYMMDD | 2017-08-01 |
| PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Gynecologic oncology |
| PublicationTitleAlternate | Gynecol Oncol |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Kirk, Kirk, Kristjanson (bb0060) 2004; 328 Klingenberg, Agresti (bb0025) 2006; 62 Herzog, Armstrong, Brady, Coleman, Einstein, Monk (bb0020) 2014; 132 Minion, Coleman, Alvarez, Herzog (bb0010) 2016; 140 Fitch, McAndrew (bb0055) 2011; 26 Manning, Dickens (bb0045) 2007; 16 Frey, Philips, Jeffries, Herzberg, Harding-Peets, Gordon (bb0015) 2014; 135 Erwin (bb0040) 2010; 15 FDA: U.S. Food and Drug Administration (bb0005) 2015 Fried, Van Ness, Byers, Towle, O'Leary, Dubin (bb0035) 2007; 22 Fried, Bradley, Towle, Allore (bb0030) 2002; 346 Fitch, McAndrew, Harth (bb0050) 2015; 2 Minion (10.1016/j.ygyno.2017.05.029_bb0010) 2016; 140 Fried (10.1016/j.ygyno.2017.05.029_bb0035) 2007; 22 FDA: U.S. Food and Drug Administration (10.1016/j.ygyno.2017.05.029_bb0005) 2015 Erwin (10.1016/j.ygyno.2017.05.029_bb0040) 2010; 15 Manning (10.1016/j.ygyno.2017.05.029_bb0045) 2007; 16 Fitch (10.1016/j.ygyno.2017.05.029_bb0050) 2015; 2 Herzog (10.1016/j.ygyno.2017.05.029_bb0020) 2014; 132 Frey (10.1016/j.ygyno.2017.05.029_bb0015) 2014; 135 Klingenberg (10.1016/j.ygyno.2017.05.029_bb0025) 2006; 62 Fitch (10.1016/j.ygyno.2017.05.029_bb0055) 2011; 26 Fried (10.1016/j.ygyno.2017.05.029_bb0030) 2002; 346 Kirk (10.1016/j.ygyno.2017.05.029_bb0060) 2004; 328 |
| References_xml | – volume: 132 start-page: 8 year: 2014 end-page: 17 ident: bb0020 article-title: Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper publication-title: Gynecol. Oncol. – volume: 15 start-page: 11 year: 2010 end-page: 12 ident: bb0040 article-title: Therapy for advanced stage cancer: what do patients want and expect? A patient advocate's perspective publication-title: Oncologist – volume: 328 start-page: 1343 year: 2004 ident: bb0060 article-title: What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study publication-title: BMJ – volume: 62 start-page: 921 year: 2006 end-page: 928 ident: bb0025 article-title: Multivariate extensions of McNemar's test publication-title: Biometrics – volume: 346 start-page: 1061 year: 2002 end-page: 1066 ident: bb0030 article-title: Understanding the treatment preferences of seriously ill patients publication-title: N. Engl. J. Med. – volume: 2 start-page: 160 year: 2015 end-page: 168 ident: bb0050 article-title: Perspectives from older adults receiving cancer treatment about the cancer-related information they receive publication-title: Asia Pac. J. Oncol. Nurs. – volume: 26 start-page: 612 year: 2011 end-page: 618 ident: bb0055 article-title: A performance measurement tool for cancer patient information and satisfaction publication-title: J. Cancer Educ. – volume: 22 start-page: 495 year: 2007 end-page: 501 ident: bb0035 article-title: Changes in preferences for life-sustaining treatment among older persons with advanced illness publication-title: J. Gen. Intern. Med. – volume: 16 start-page: 33 year: 2007 end-page: 38 ident: bb0045 article-title: Cancer Information and Support Centres: fixing parts cancer drugs cannot reach publication-title: Eur. J. Cancer Care (Engl). – volume: 135 start-page: 261 year: 2014 end-page: 265 ident: bb0015 article-title: A qualitative study of ovarian cancer survivors' perceptions of endpoints and goals of care publication-title: Gynecol. Oncol. – volume: 140 start-page: 193 year: 2016 end-page: 198 ident: bb0010 article-title: Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance publication-title: Gynecol. Oncol. – year: 2015 ident: bb0005 article-title: FDA Public Workshop: Ovarian Cancer Endpoints Workshop – volume: 15 start-page: 11 issue: Suppl. 1 year: 2010 ident: 10.1016/j.ygyno.2017.05.029_bb0040 article-title: Therapy for advanced stage cancer: what do patients want and expect? A patient advocate's perspective publication-title: Oncologist doi: 10.1634/theoncologist.2010-S1-11 – volume: 135 start-page: 261 year: 2014 ident: 10.1016/j.ygyno.2017.05.029_bb0015 article-title: A qualitative study of ovarian cancer survivors' perceptions of endpoints and goals of care publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2014.09.008 – year: 2015 ident: 10.1016/j.ygyno.2017.05.029_bb0005 – volume: 346 start-page: 1061 year: 2002 ident: 10.1016/j.ygyno.2017.05.029_bb0030 article-title: Understanding the treatment preferences of seriously ill patients publication-title: N. Engl. J. Med. doi: 10.1056/NEJMsa012528 – volume: 26 start-page: 612 year: 2011 ident: 10.1016/j.ygyno.2017.05.029_bb0055 article-title: A performance measurement tool for cancer patient information and satisfaction publication-title: J. Cancer Educ. doi: 10.1007/s13187-011-0260-9 – volume: 140 start-page: 193 year: 2016 ident: 10.1016/j.ygyno.2017.05.029_bb0010 article-title: Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2015.11.030 – volume: 16 start-page: 33 year: 2007 ident: 10.1016/j.ygyno.2017.05.029_bb0045 article-title: Cancer Information and Support Centres: fixing parts cancer drugs cannot reach publication-title: Eur. J. Cancer Care (Engl). doi: 10.1111/j.1365-2354.2006.00699.x – volume: 328 start-page: 1343 year: 2004 ident: 10.1016/j.ygyno.2017.05.029_bb0060 article-title: What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study publication-title: BMJ doi: 10.1136/bmj.38103.423576.55 – volume: 22 start-page: 495 year: 2007 ident: 10.1016/j.ygyno.2017.05.029_bb0035 article-title: Changes in preferences for life-sustaining treatment among older persons with advanced illness publication-title: J. Gen. Intern. Med. doi: 10.1007/s11606-007-0104-9 – volume: 132 start-page: 8 year: 2014 ident: 10.1016/j.ygyno.2017.05.029_bb0020 article-title: Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2013.11.008 – volume: 62 start-page: 921 year: 2006 ident: 10.1016/j.ygyno.2017.05.029_bb0025 article-title: Multivariate extensions of McNemar's test publication-title: Biometrics doi: 10.1111/j.1541-0420.2006.00525.x – volume: 2 start-page: 160 year: 2015 ident: 10.1016/j.ygyno.2017.05.029_bb0050 article-title: Perspectives from older adults receiving cancer treatment about the cancer-related information they receive publication-title: Asia Pac. J. Oncol. Nurs. doi: 10.4103/2347-5625.160971 |
| SSID | ssj0003012 |
| Score | 2.3210583 |
| Snippet | Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease. We sought to... Abstract Objectives Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease.... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 386 |
| SubjectTerms | Adolescent Adult Aged Alopecia - chemically induced Alopecia - psychology Antineoplastic Agents - adverse effects Arthralgia - chemically induced Arthralgia - psychology Attitude to Health Constipation - chemically induced Constipation - psychology Diarrhea - chemically induced Diarrhea - psychology Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - psychology Fatigue - chemically induced Fatigue - psychology Female Gastroesophageal Reflux - chemically induced Gastroesophageal Reflux - psychology Hematology, Oncology and Palliative Medicine Hospitalization Humans Memory Disorders - chemically induced Memory Disorders - psychology Middle Aged Nausea - chemically induced Nausea - psychology Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - psychology Neoplasm Staging Obstetrics and Gynecology Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - psychology Pain - chemically induced Pain - psychology Patient Care Planning Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - psychology Quality of Life Remission Induction Sexual Dysfunction, Physiological - chemically induced Sexual Dysfunction, Physiological - psychology Surveys and Questionnaires Survivors - psychology Vomiting - chemically induced Vomiting - psychology Young Adult |
| Title | Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0090825817308855 https://www.clinicalkey.es/playcontent/1-s2.0-S0090825817308855 https://dx.doi.org/10.1016/j.ygyno.2017.05.029 https://www.ncbi.nlm.nih.gov/pubmed/28602549 https://www.proquest.com/docview/1908798040 |
| Volume | 146 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1095-6859 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003012 issn: 0090-8258 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9owFLZoO017mXYf3VZ50rQ9sFQkxHH8WE2wG6WTSiXeLCdxOirkUAII9nv2Q3cc26FVL-se9hKhKI6B8-Xc8p1zEHonExYHWUg86dOOF6ZB5gkItLwkyiSEEwlYsKrPbJ8OBvFoxH40Gr9dLcxyQpWKVys2_a-ihnMgbF06-w_irm8KJ-AzCB2OIHY43knwR0sIf-GpTbU8Z61yAcpgWcwqtoRINYulqhLQ3ICaZK5ndtbUDgkaS_eiFWXrtLDdlQ1BrKpEaGnSZ-Wv2h00232sFrang3V0P6-VTI1ibRUqvZS8781MnvxQTkDsYpNp1QQSMx1ZqbHcFEl8L2CLX66MW1yYgfxzbTKyxwIiAmVz2zaJAYbRUeic3gVPz4ti2xxcXnPOKWubsBxfCJqN6u2YltpXTILJTpztr0_XSld7-qZVq82zXGrAPTjivZN-nw-7o-H76bmnZ5Ppd_h2UMsW2gkoYaA7dw6-dkffaosPStK8Vbdf2HW3qniEV_a9yQO6KcKpPJ3hI_TQhij4wEDrMWpI9QTdP7QkjKdoZRGGjfxxjbAPeIMvXOS4xhfW-MIWX9jiC4sSV_jSl2p8YYMvrPGFAV_u_jW-nqGTXnf46YtnB3h4aRjSuZdQAQFFngSJ9EVOOm3J8oRmESNEprFI8synUiQkZZmuqM5lh7BAUpmGLBK6seVztK0KJV8izMDZohF49-08D-MwS0gmozwXfphBzJOETRS4P5Wntru9HrIy4Y7GeMYrSXAtCd4mHCTRRB_rRVPT3OX2y0MnLe7qlsHSckDa7cvodctkaZVGyX1eBrzNjyHe0RmbGNQmGH9CmiiqV1qH2Di6f9_yrQMTB3Oh3wEKJYsFbAU7UBaD6W6iFwZl9U8P9Dw6ErLdO6x-hR5snuPXaHs-W8g36F66nI_L2R7aoqN4zz4mfwCCk_A0 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ovarian+cancer+survivors%27+acceptance+of+treatment+side+effects+evolves+as+goals+of+care+change+over+the+cancer+continuum&rft.jtitle=Gynecologic+oncology&rft.au=Frey%2C+Melissa+K&rft.au=Ellis%2C+Annie+E&rft.au=Koontz%2C+Laura+M&rft.au=Shyne%2C+Savannah&rft.date=2017-08-01&rft.issn=1095-6859&rft.eissn=1095-6859&rft.volume=146&rft.issue=2&rft.spage=386&rft_id=info:doi/10.1016%2Fj.ygyno.2017.05.029&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |